newsfilter
← Latest News
GlobeNewswire·

Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting

  • Lantheus Holdings, Inc. announced new radiodiagnostic data to be presented at the 2026 Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting in Los Angeles, CA.
  • The meeting is scheduled for May 30 – June 2, 2026, with two specific presentations scheduled for June 1 & 2, 2026.
  • On Monday, June 1, 2026, a poster presentation titled "Impact of PSMA-PET with Piflufolastat F18 on Prostate Cancer Management for Patients with Low or Ultra-low Prostate-Specific Antigen Levels after Definitive Treatment" will be delivered by Neal Shore of the Carolina Urologic Research Center.
  • On Tuesday, June 2, 2026, an oral presentation titled "Diagnostic performance of 18F-GP1 PET/CT for acute deep vein thrombosis of the lower extremities in symptomatic patients: a phase 2, open-label, non-randomized study" will be delivered by Sangwon Han of Asan Medical Center, University of Ulsan College of Medicine.
  • Lantheus is a radiopharmaceutical-focused company headquartered in Bedford, Massachusetts, with offices in New Jersey, Canada, Germany, Sweden, Switzerland, & the United Kingdom, having provided solutions for 70 years.